【全球有67%的人感染了這種「無法治療」的病毒】
世界衛生組織最新發佈的研究顯示，全球約有37億人，感染HSV-1，佔總人口的67%。研究者表示，這樣的數字十分讓人擔心，因為在許多地方，HSV-1最常見的傳染方式正在改變。
我們大多認為，HSV-1是口腔皰疹的元兇，HSV-2則是藉由性行為傳染。感染皰疹的人，不一定會發病，但一輩子都會帶有病毒，因為目前並沒有治療方法；不過，帶有病毒的人不一定會出現病癥。
According to the World Health Organisation, two-thirds of the world's population under 50 have the highly infectious herpes virus that causes cold sores around the mouth. So, is prevention or therapy the better method of treatment? http://reut.rs/1XB5T3m
根據世界健康組織的三分之二的世界人口在 50 有高度傳染性的皰疹病毒導致冷瘡口的周圍。所以，是預防或治療治療的更好方法嗎?HTTP://reut.rs/1XB5T3m
You probably have herpes, the WHO says
GENEVA |
Two-thirds of the world's population under 50 have the highly infectious herpes virus that causes cold sores around the mouth, the World Health Organization said on Wednesday, in its first estimate of global prevalence of the disease.
More than 3.7 billion people under the age of 50 suffer from the herpes simplex virus type 1 (HSV-1), usually after catching it in childhood, according to a the WHO study.
That is in addition to 417 million people in the 17-49 age range who have the other form of the disease, HSV-2, which causes genital herpes.
HSV-1 normally causes mouth ulcers rather than genital infection, but it is becoming an increasing cause of genital infection too, mainly in rich countries.
That is because improved hygiene in rich countries is lowering HSV-1 infection rates in childhood, leaving young people more at risk of catching it via oral sex when they become sexually active.
HSV-2 can increase the risk of catching and spreading HIV, the disease that causes AIDS. Little is known about any link between HSV-1 and HIV/AIDS, although it can lead to other serious complications such as encephalitis.
"We really need to accelerate the development of vaccines against herpes simplex virus, and if a vaccine designed to prevent HSV-2 infection also prevented HSV-1, it would have far reaching benefits," said Sami Gottlieb, a WHO medical officer.
Nathalie Broutet, also a WHO medical officer, said the U.S. National Institutes of Health and companies including GlaxoSmithKline Plc were involved in trials to determine whether a therapeutic or preventative vaccine was preferable.
Gottlieb said GSK had previously abandoned a vaccine trial after finding the product was not effective against HSV-2, although it did show some efficacy against HSV-1.
"That was interesting and promising and gave a proof of concept that these vaccines can be developed. There's a lot of work ongoing and we're hopeful that we'll have an HSV vaccine in the future," she said.
Several phase-1 and phase-2 trials were underway, she said. Genocea Biosciences Inc recently dropped work on a pneumonia vaccine in favor of its more promising work on genital herpes.
(Reporting by Tom Miles; Editing by Gareth Jones)
沒有留言:
張貼留言